{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260618416609/en/U.S.-FDA-Approves-an-Additional-Indication-for-CAPVAXIVE%C2%AE-Pneumococcal-21-valent-Conjugate-Vaccine-in-Children-and-Adolescents-Aged-2-through-17-at-Increased-Risk-for-Pneumococcal-Disease", "message": "News view counter 806828 successfully enlarged"}